Savara (SVRA) Liabilities and Shareholders Equity (2010 - 2026)
Savara (SVRA) reported Liabilities and Shareholders Equity of $221.6 million for Q1 2026, up 17.08% year-over-year from $189.3 million in Q1 2025, and down 12.54% on a QoQ basis from $253.4 million in Q4 2025.
Savara (SVRA) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $221.6 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 17.08% year-over-year to $221.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $779.8 million (changed 0.12% YoY) and the FY2025 annual result came in at $253.4 million, up 19.05% from the prior year.
- Liabilities and Shareholders Equity retreated to $221.6 million in Q1 2026 per SVRA's latest filing, from $253.4 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $253.4 million in Q4 2025 and bottomed at $119.8 million in Q2 2023.
- The 5-year median for Liabilities and Shareholders Equity is $163.8 million (2025), against an average of $172.8 million.
- The widest annual swing landed in 2024, when Liabilities and Shareholders Equity soared 31.17%; it then plunged 40.99% in 2025.
- Tracing SVRA's Liabilities and Shareholders Equity over 5 years: stood at $139.8 million in 2022, then advanced by 27.03% to $177.6 million in 2023, then gained by 19.89% to $212.9 million in 2024, then gained by 19.05% to $253.4 million in 2025, then retreated by 12.54% to $221.6 million in 2026.
- Per Business Quant, the three latest SVRA Liabilities and Shareholders Equity figures stand at $221.6 million (Q1 2026), $253.4 million (Q4 2025), and $140.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 221.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 221.65 Mn |
| Dec 31, 2025 | 253.44 Mn |
| Sep 30, 2025 | 140.92 Mn |
| Jun 30, 2025 | 163.77 Mn |
| Mar 31, 2025 | 189.32 Mn |
| Dec 31, 2024 | 212.88 Mn |
| Sep 30, 2024 | 238.82 Mn |
| Jun 30, 2024 | 139.67 Mn |
| Mar 31, 2024 | 158.30 Mn |
| Dec 31, 2023 | 177.56 Mn |
| Sep 30, 2023 | 182.07 Mn |
| Jun 30, 2023 | 119.83 Mn |
| Mar 31, 2023 | 129.36 Mn |
| Dec 31, 2022 | 139.78 Mn |
| Sep 30, 2022 | 147.76 Mn |
| Jun 30, 2022 | 156.78 Mn |
| Mar 31, 2022 | 166.21 Mn |
| Dec 31, 2021 | 176.60 Mn |
| Sep 30, 2021 | 187.27 Mn |
| Jun 30, 2021 | 196.43 Mn |
| Mar 31, 2021 | 207.63 Mn |
| Dec 31, 2020 | 97.75 Mn |
| Sep 30, 2020 | 109.34 Mn |
| Jun 30, 2020 | 115.15 Mn |
| Mar 31, 2020 | 119.98 Mn |
| Dec 31, 2019 | 136.20 Mn |
| Sep 30, 2019 | 140.63 Mn |
| Jun 30, 2019 | 147.33 Mn |
| Mar 31, 2019 | 148.26 Mn |
| Dec 31, 2018 | 152.29 Mn |
| Sep 30, 2018 | 155.12 Mn |
| Jun 30, 2018 | 117.94 Mn |
| Mar 31, 2018 | 128.87 Mn |
| Dec 31, 2017 | 159.63 Mn |
| Sep 30, 2017 | 118.89 Mn |
| Jun 30, 2017 | 125.77 Mn |
| Mar 31, 2017 | 13.89 Mn |
| Dec 31, 2016 | 28.93 Mn |
| Sep 30, 2016 | 40.12 Mn |
| Jun 30, 2016 | 47.68 Mn |
| Mar 31, 2016 | 50.15 Mn |
| Dec 31, 2015 | 54.22 Mn |
| Sep 30, 2015 | 63.44 Mn |
| Jun 30, 2015 | 56.76 Mn |
| Mar 31, 2015 | 62.72 Mn |
| Dec 31, 2014 | 70.50 Mn |
| Sep 30, 2014 | 56.16 Mn |
| Jun 30, 2014 | 59.37 Mn |
| Mar 31, 2014 | 62.36 Mn |
| Dec 31, 2013 | 55.25 Mn |
| Sep 30, 2013 | 59.65 Mn |
| Jun 30, 2013 | 63.84 Mn |
| Mar 31, 2013 | 42.33 Mn |
| Dec 31, 2012 | 46.97 Mn |
| Sep 30, 2012 | 51.56 Mn |
| Jun 30, 2012 | 54.18 Mn |
| Mar 31, 2012 | 57.51 Mn |
| Dec 31, 2011 | 61.86 Mn |
| Sep 30, 2011 | 46.27 Mn |
| Jun 30, 2011 | 50.16 Mn |
| Dec 31, 2010 | 28.49 Mn |